Immunovant IMVT
$31.77 −$0.75 (-2.31%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $31.51 -0.82%
Open$32.26
Prev close$32.52
Day range$31.61 – $32.77
Volume704.9K
Market cap$6.57B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±12.8%last 9 reports
Closed higher6 of 967% of the time
Best reaction+35.3%
Worst reaction-38.0%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2027/Q2 | 9 Nov 2026 | Pre Market | ±11.6% | +15.13% | Bigger than priced |
| 2027/Q1 | 6 Aug 2026 | Pre Market | ±11.7% | +1.17% | Within range |
| 2026/Q4 | 20 May 2026 | Pre Market | ±18.6% | +35.26% | Bigger than priced |
| 2026/Q3 | 6 Feb 2026 | Pre Market | ±14.4% | +12.43% | Within range |
| 2026/Q2 | 10 Nov 2025 | Pre Market | ±16.4% | +0.09% | Within range |
| 2025/Q2 | 7 Nov 2024 | Pre Market | ±13.3% | -4.74% | Within range |
| 2022/Q4 | 8 Jun 2022 | Pre Market | ±28.1% | -8.20% | Within range |
| 2022/Q1 | 9 Aug 2021 | Pre Market | ±19.7% | +0.39% | Within range |
| 2021/Q4 | 1 Jun 2021 | Pre Market | ±21.0% | -37.99% | Bigger than priced |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q2, ended Sep 2026
Revenue$0.00
Operating profit-$104.16M+21.0% YoY
Net profit-$97.25M+23.1% YoY
Diluted EPS-$0.47+35.6% YoY
Free cash flow-$83.22M+18.8% YoY
Operating cash flow-$83.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Return on equity-86.5%
Return on assets-75.7%
Return on invested capital-91.2%
Current ratio7.31
Liabilities / assets13.7%
Cash & investments$722.27M
Net cash (debt)$722.27M
No comments yet — be the first to weigh in on IMVT.
Sign in to join the discussion.